Botulinum toxin type A for chronic neurovascular and myofascial facial pain: a comprehensive case report.

This article reports on a female patient with chronic orofacial pain, followed up for 12 years. She described her pain as throbbing with intermittent pain attacks, and frequently accompanied by symptoms such as photophobia, phonophobia, and nausea. This was associated with myofascial pain of masticatory muscles, which were very painful on palpation. The patient was diagnosed with a complex pain profile that included chronic facial migraine, chronic masticatory myofascial pain, nonspecific neuropathic components, and generalized facial hypersensitivity. Despite the diversity of pharmacologic treatments, clinical benefit was limited and transient, with many medications discontinued due to adverse effects or lack of efficacy. The successful use of botulinum toxin type A (BoNT-A; Dysport) in treating this patient is presented. Planned administration of BoNT-A into anatomically and symptomatically defined trigger zones produced significant and sustained relief of migraine symptoms, followed up for 2 years. However, mild residual myofascial discomfort persisted. BoNT-A administration has the advantage of providing periodic rather than daily prophylactic treatment, the latter utilized by the present conventional method.

Authors

Publication Details

Journal
PubMed
Published
2026-02-27
DOI
https://doi.org/10.3290/j.qi.b6739961
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Botulinum toxin type A for chronic neurovascular and myofascial facial pain: a comprehensive case report.

A.V. Novikov, Yair Sharav, Yaron Haviv
PubMed
Botulinum Toxin and Related Neurological Disorders
article

Botulinum toxin type A for chronic neurovascular and myofascial facial pain: a comprehensive case report.

A.V. Novikov, Yair Sharav, Yaron Haviv
article en

Abstract

This article reports on a female patient with chronic orofacial pain, followed up for 12 years. She described her pain as throbbing with intermittent pain attacks, and frequently accompanied by symptoms such as photophobia, phonophobia, and nausea. This was associated with myofascial pain of masticatory muscles, which were very painful on palpation. The patient was diagnosed with a complex pain profile that included chronic facial migraine, chronic masticatory myofascial pain, nonspecific neuropathic components, and generalized facial hypersensitivity. Despite the diversity of pharmacologic treatments, clinical benefit was limited and transient, with many medications discontinued due to adverse effects or lack of efficacy. The successful use of botulinum toxin type A (BoNT-A; Dysport) in treating this patient is presented. Planned administration of BoNT-A into anatomically and symptomatically defined trigger zones produced significant and sustained relief of migraine symptoms, followed up for 2 years. However, mild residual myofascial discomfort persisted. BoNT-A administration has the advantage of providing periodic rather than daily prophylactic treatment, the latter utilized by the present conventional method.

PubMedVol. 57(2)
Openalex Percentile: Top 100%
Botulinum Toxin and Related Neurological Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Botulinum toxin type A for chronic neurovascular and myofascial facial pain: a comprehensive case report. — A.V. Novikov, Yair Sharav, et al. · PubMed (2026) | TGRS Research Map | TGRS